PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
0.49%
Gross profit growth of 0.49% while AVXL is zero. Bruce Berkowitz would see if minimal improvements could expand further.
56.85%
EBIT growth 50-75% of AVXL's 100.00%. Martin Whitman would suspect suboptimal resource allocation.
54.90%
Operating income growth at 50-75% of AVXL's 100.00%. Martin Whitman would doubt the firm’s ability to compete efficiently.
56.85%
Net income growth at 50-75% of AVXL's 100.00%. Martin Whitman would question fundamental disadvantages in expenses or demand.
56.86%
EPS growth above 1.5x AVXL's 7.14%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
56.86%
Diluted EPS growth above 1.5x AVXL's 7.14%. David Dodd would see if there's a robust moat protecting these shareholder gains.
-0.00%
Share reduction while AVXL is at 0.32%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.00%
Reduced diluted shares while AVXL is at 0.32%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
28.81%
OCF growth at 50-75% of AVXL's 51.68%. Martin Whitman would question if the firm lags in monetizing sales effectively.
28.81%
FCF growth 50-75% of AVXL's 51.68%. Martin Whitman would see if structural disadvantages exist in generating free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 3Y CAGR while AVXL stands at 0.00%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
95.99%
Positive long-term OCF/share growth while AVXL is negative. John Neff would see a structural advantage in sustained cash generation.
56.40%
5Y OCF/share CAGR above 1.5x AVXL's 23.68%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
-114.69%
Negative 3Y OCF/share CAGR while AVXL stands at 45.55%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
96.39%
Similar net income/share CAGR to AVXL's 100.00%. Walter Schloss would see parallel tailwinds or expansions for both firms.
45.76%
Below 50% of AVXL's 100.00%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
32.63%
Below 50% of AVXL's 100.00%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
-96.80%
Negative equity/share CAGR over 10 years while AVXL stands at 257.27%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-86.34%
Negative 5Y equity/share growth while AVXL is at 176.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-81.50%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.20%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-26.00%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-9.98%
We’re deleveraging while AVXL stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-36.64%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-70.64%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.